SCHEMBL27224263

SCHEMBL27224263

O=C1N/C(=C\c2ccc3nccc(-c4ccncc4)c3c2)C(=O)S1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 10/20 0.76
▸ CLK1 P49759 5/20 0.76
▸ DYRK1A Q13627 5/20 0.76
▸ CSNK2A2 P19784 4/20 0.76
▸ PIK3CD O00329 3/20 0.76
▸ PIK3CG P48736 3/20 0.76
▸ PIM1 P11309 3/20 0.76
▸ PIK3CB P42338 2/20 0.76
▸ MTOR P42345 2/20 0.76
▸ CLK2 P49760 2/20 0.76
▸ GAK O14976 1/20 0.76
▸ RPS6KA4 O75676 1/20 0.76
▸ STK10 O94804 1/20 0.76
▸ MAP2K2 P36507 1/20 0.76
▸ CSNK1D P48730 1/20 0.76
▸ CSNK1G2 P78368 1/20 0.76
▸ MAP2K1 Q02750 1/20 0.76
▸ AAK1 Q2M2I8 1/20 0.76
▸ Q6ZSR9 Q6ZSR9 1/20 0.76
▸ TAOK1 Q7L7X3 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13739026 1.00 PIK3CA (0.76) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
Gsk-1059615 SCHEMBL1805561 0.86 PIK3CA (1.00) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
Gsk-1059615 SCHEMBL1805557 0.86 PIK3CA (1.00) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
Gsk-1059615 SCHEMBL29381321 0.86 PIK3CA (1.00) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
Gsk-1059615 SCHEMBL1805560 0.86 PIK3CA (1.00) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
Gsk-1059615 SCHEMBL29351551 0.86 PIK3CA (1.00) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
SCHEMBL1808883 0.77 CLK1 (0.69) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
SCHEMBL30827802 0.76 PIK3CA (0.60) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
SCHEMBL732106 0.76 PIK3CA (0.60) PIK3CACLK1DYRK1ACSNK2A2PIK3CD
SCHEMBL729541 0.75 PIK3CA (0.77) PIK3CACLK1DYRK1ACSNK2A2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166759-A1 COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME ANGIEX, INC. 2024-05-23 — — US disclosed
CN-107667092-B Formylated N-heterocyclic derivatives as FGFR4 inhibitors 诺华股份有限公司 2021-05-28 — — CN disclosed
Send feedback